ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer
The identification of a T cell receptor targeting a clinically relevant HBV epitope and ANKRD11 as a key epigenetic regulator of CD8+ T cell dysfunction in chronic infection and tumors position ANKRD11 as a promising immunotherapy target for chronic HBV infection and cancer.